Inergetics is a leading developer of advanced proprietary nutritional products that are designed to improve overall health, physical recovery, athletic performance and quality of life for patients and consumers. The company offers a range of supplements formulated for wholesale distribution, as well as a collection of proven retail product lines – including Martha Stewart™ Essentials, Surgex® Sports Nutrition, Bikini Ready® Lifestyle, SlimTrim, OmEssentials® and Nulief™. Inergetics’s selection of trusted brands is available domestically and internationally at thousands of premier health and wellness retailers.

As an established player in the nutritional supplement industry, Inergetics has access to one of the fastest growing markets in the world. According to a report by Forbes, the vitamins, minerals and supplements (VMS) market produced approximately $32 billion in revenue in 2012, and that figure is expected to top $60 billion within the next six years. Look for the company to capitalize on this mainstream growth in order to provide a platform for sustainable returns in the years to come.

In recent months, Inergetics has made progress toward capitalizing on another emerging opportunity: the cannabis industry. In March, the company officially launched its Nulief brand of cannabinoid-based nutritional supplements. By targeting these products toward medical marijuana dispensaries throughout the United States, Inergetics will gain a foothold in another of the country’s most rapidly expanding industries.

Commercialization of the Nulief brand represents a major step in the advancement of holistic medicine. Cannabidiol (CBD), the supplement’s primary ingredient, has emerged as a key element in maintaining stable internal conditions within the human body. As a result, Nulief has been shown effective in minimizing discomfort without inflicting the psychoactive effects associated with traditional medicinal marijuana products.

“Nulief is a nutraceutical that takes Inergetics one step closer to realizing our vision of bringing a suite of farm to formula products to market,” Mike James, chief executive officer of Inergetics, stated in a news release. “Making Nulief available to dispensary customers is our initial step toward bringing an accessible CDB-based line to the entire market through our range of mass market national and international retail partners.”

Last month, Inergetics further demonstrated its commitment to innovation through the announcement of two new next-generation brands designed to target current consumer market trends. For prospective shareholders, the company’s continued efforts toward meeting the evolving demands of the retail supplements market could foreshadow an opportunity for improved financial results in the coming months.

For more information, visit www.inergetics.com

View Systems, an established security services provider, is continuing to increase its market share in the booming security industry through the development and commercialization of its groundbreaking ViewScan concealed weapons detection (CWD) system. In recent months, the company has made strides toward sustainable growth by targeting its marketing efforts in the direction of potentially expansive security opportunities – including schools, prisons, police stations, events and building lobbies seeking heightened and efficient security.

Unlike traditional CWD systems, the ViewScan platform accelerates the accurate detection of threat objects by eliminating many of the false positives associated with non-threatening personal artifacts, such as coins, keys and belt buckles. In June, View Systems built upon its industry-leading technology by initiating manufacturing efforts on an enhanced ViewScan product. This product update adds improved threat recognition and subject identification capabilities to allow for more comprehensive control of security screening processes.

“Our ViewScan weapon detection system boasts numerous advantages over ordinary metal detectors on the market,” Gunther Than, chief executive officer of View Systems, stated in a news release. “We’re excited about the momentum we have moving forward as more customers recognize the benefits of our system in providing efficient security measures for their facilities.”

By expanding its presence in the security industry, View Systems is opening the door for near limitless growth moving forward. As a manufacturer and distributor of products in the thriving contraband detection market, the company’s technology will likely remain in high demand as the global threats to governments and businesses create a sustainable need for improved screening capabilities. According to a report by IBISWorld, the security services market is currently valued at approximately $31 billion, and continued growth is expected in the years to come.

In the first quarter of 2015, the company demonstrated the immense market potential of its technology by realizing a significant increase in ViewScan product sales. For the period, the company recorded $46,900 in revenue attributed to ViewScan sales and installations, which was an increase of more than 40 percent over the first quarter of 2014. Look for View Systems to build on this progress in the months to come, providing an opportunity to maximize returns and promote increased shareholder value.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

Boreal Water Collection recently took a major step toward strengthening its balance sheet when it announced the retirement of all outstanding convertible notes held by financing companies. Since October 2014, the company has not entered into any new convertible promissory note agreements, and its management team is confident that it can continue adequately funding operations and expansion without the use of this unpredictable form of financing in the future.

“Retiring all of the convertible debt was a major corporate goal set by our management team,” Francine Lavoie, chief executive officer of Boreal, stated in a news release. “With the uncertainty in our equity structure caused by this type of debt instruments finally behind us, we can now fully focus on growing our business and adding value for our shareholders.”

In total, Boreal’s debt reduction efforts have resulted in more than $830,000 of debts being converted into shares, clearing the way for continued expansion of the company’s market share in the coming months.

“A significant amount of the company’s operating loss and dilution to shareholders was attributable to these convertible note instruments,” continued Lavoie. “While such debt served a purpose during a time when we were investing in creating revenues and developing new products, we are happy to be moving ahead without this type of debt instrument.”

Moving forward, Boreal is now in a formidable financial position to build upon its widespread personalized bottled water distribution network, which is already among the most extensive in North America. In May, the company confirmed its expansion efforts by announcing that its specialty ‘Boreal’s Baby Water’ product would be offered in more than 300 supermarkets in China.

Last month, the company solidified its position in the Asian market by claiming the silver medal at the prestigious International High-End Water Tasting Contest in Guangzhou, China. Boreal’s potential for growth within this thirsty market is immense. Mainly for health and safety reasons, the demand for pristine drinking water in China is typically higher than similar demand in North American markets. In 2012, the Asian nation’s high-end drinking water market was estimated at $1.5 billion, with a forecast 20 percent annual growth rate in the years to come.

For prospective shareholders, Boreal’s recent progress in expanding its distribution channels and strengthening its balance sheet makes the company an intriguing investment opportunity. These strategic moves should allow Boreal to effectively reduce uncertainty in its equity structure while adding considerable value for its shareholders.

For more information, visit www.borealwater.com

Arrayit is a leading life sciences company providing innovative products and services to empower exploration of the human genome, as well as the genomes of plants and animals. The company’s patented microarray manufacturing platform and proprietary VIP™ genotyping technology are used in a wide variety of research centers around the world – including research laboratories, pharmaceutical businesses, universities, biotechnology firms, hospitals, government agencies and nonprofit research organizations. By developing and commercializing technology that provides novel insights into the function of genes and proteins, Arrayit opens the door for improved disease diagnostics, safer medicines and more nutritional crop plants.

Since 1999, the company has built a powerful portfolio of intellectual property that includes more than 650 life sciences products. In total, Arrayit’s products and services, which are used in the life sciences, pharmaceutical and diagnostics markets, account for an estimated $690 billion in annual revenue. In May, the company built on its strong industry performance by teaming with Vivos on its Global Genome Vault, the only private human DNA vault on Earth. Through this partnership, Arrayit will optimize Vivos’s DNA collection efforts by providing its innovative blood card technology, which allows for the rapid collection, separation, drying and storage of human genomic DNA in a format that is both permanent and highly miniaturized.

“We are pleased to partner with Vivos on this ambitious scientific project,” Rene Schena, chief executive officer of Arrayit, stated in a news release. “Rapid advances in biomedical research offer the promise of future scientific breakthroughs based on high quality archival genomic DNA.”

In recent months, the company has utilized the marketability of its products and services to realize strong financial results. In 2014, Arrayit recorded a 128 percent increase in annual gross profit, demonstrating the immense market potential of its groundbreaking offerings. Look for Arrayit to continue leveraging its diverse product portfolio in the future, providing a platform for sustainable industry growth.

For prospective shareholders, Arrayit’s extensive customer base, which spans more than 50 countries, and innovative portfolio of products and services make the company an intriguing investment opportunity. Look for Arrayit to continue utilizing its proprietary microarray platform in order to expand its market share in the genetic research, pharmaceutical and diagnostic communities moving forward.

For more information, visit www.arrayit.com

The One World Doll Project, a subsidiary of One World Holdings, Inc. (OWOO), announced that it was featured today in a New York Daily News feature article entitled “Diverse dolls like the Prettie Girls! Tween Scene help retailers like Walmart toy with change.” Based in New York City, The New York Daily News is the fourth most widely circulated daily newspaper in the United States.

“With media coverage from the likes of CNN, Huffington Post, USA Today and now New York Daily News, we are confident this kind of publicity will help to solidify The Prettie Girls! Tween Scene dolls as a ‘must have’ for Christmas 2015,” stated Trent T. Daniel, Founder of One World Holdings, Inc. “We believe that getting the attention of major media outlets such as The New York Daily News makes a strong statement about The Prettie Girls! potential to become a popular mainstream product.”

An online version of the article can be viewed on The New York Daily News website at nydailynews.com at http://www.nydailynews.com/life-style/diverse-dolls-inspire-retailers-toy-change-article-1.2283279.

For more information on One World Holdings, visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

FastFunds Financial announced that Cannabis Merchant Financial Solutions, Inc. (CMFS), a subsidiary, has entered into a sales representation agreement with Evergreen Licensing of Northridge, California (Evergreen) for the Tommy Chong Green Card.

Evergreen is the exclusive distribution company in the state of California for Tommy Chong. To date, the distribution company and its affiliated entities have successfully placed merchandize in approximately 300 dispensaries. Evergreen will be marketing the Tommy Chong Green Card to a targeted list of dispensary owners and key decision makers within its well-established California based distribution network, which includes some of the most successful dispensaries in the cannabis industry.

Kurt Martig, President of CMFS, stated that the signing of this is a major step forward in the company’s plan to achieve national distribution of the Tommy Chong Green Card. California is significant as it is one of the largest states in terms of dollar volume of sales and the number of operating dispensaries.

For those unfamiliar with the Tommy Chong Green Card, it functions as a pre-paid loyalty debit card with a turnkey customer rewards technology. In addition, the card functions as a reloadable stored value card that can be used to purchase merchandise at the participating dispensary.

Evergreen Licensing is a leading company in the emerging legal cannabis industry, with a focus on product and brand acquisition, development and distribution. Evergreen holds licensing rights for other high profile brands and individuals. Most notably, Evergreen is the exclusive distribution company in the state of California for comedian, actor and marijuana Icon, Tommy Chong. This provides Evergreen the right to distribute and license the Tommy Chong brand via its vast network of California based collective operators, for the purpose of developing and distributing premium Tommy Chong branded and endorsed, THC based products within the largest legal state. The Evergreen team is comprised of industry veterans, including peer respected cultivators, leading cannabis attorneys and physicians, dispensary operators, and branding experts – each having over a decade of experience in the industry.

For more information on FastFunds Financial Corp., visit www.fastfundsfinancial.com

Let us hear your thoughts: Fastfunds Financial Corp. Message Board

Earlier today, the Aristocrat Group Corp. announced that its flagship product, RWB Ultra-Premium Handcrafted Vodka, has been approved for sale in the state of Louisiana. According to the press release, a shipment of the made-in-the-USA vodka is already on its way there.

“Louisiana is an important market for distilled spirits—particularly the state’s gaming resorts and nightlife tourism,” said ASCC CEO Robert Federowicz. “We have been working to secure distribution there for some time, but we are especially pleased to announce this growth in distribution just prior to our attendance at Tales of the Cocktail in New Orleans. We look forward to introducing this smooth and authentic spirit to a whole new wave of buyers and afficianados.”

ASCC has made growth its top priority since the debut of RWB Vodka. Following a dedicated, nationwide marketing push that has included tasting tours, sports sponsorships and artist endorsements, the company has built considerable momentum heading into the summer. In April, the company celebrated a new all-time high in total sales of RWB Vodka, and expects the numbers for May to be even better once they’re released.

RWB Handcrafted Ultra-Premium Vodka is currently available at hundreds of retail locations and online, with talks underway to make the brand available in Canada and Mexico. Recently, the company boosted business dramatically by unveiling a new brand, Big Box Vodka, poised to offer consumers an unprecedented level of convenience and creating a whole new market segment in the process.

For more information on the Aristocrat Group, visit www.aristocratgroupcorp.com/investors

Let us hear your thoughts: The Aristocrat Group Corp. Message Board

CorMedix, Inc. (NYSE MKT: CRMD) is a commercial-stage biopharmaceutical company seeking to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The company’s first commercial product, Neutrolin®, is currently marketed in Europe as a catheter lock solution for the prevention of catheter-related bloodstream infections in hemodialysis, oncology and critical care patients. In the coming months, CorMedix plans to expand commercial distribution of Neutrolin into the United States, Asia, the Middle East, South America and Africa following appropriate regulatory approval.

In June, CorMedix took a significant step toward the eventual commercialization of its innovative product in the United States when it received positive feedback from the FDA regarding a second pivotal clinical trial protocol. This protocol is designed to assess Neutrolin as a catheter lock solution in oncology patients who require total parental nutrition. Previously, the FDA also reviewed the company’s phase III clinical trial protocol to evaluate the use of Neutrolin in hemodialysis patients. With this feedback received, CorMedix expects to initiate the corresponding clinical trials in the fourth quarter of this year. Since the company’s product received fast track designation earlier this year, these trials will be eligible for priority review of FDA submissions and accelerated clinical results in the future.

“CorMedix is thankful for the valuable feedback provided by the FDA, and we are encouraged by their continued enthusiasm and support of Neutrolin,” Randy Milby, chief executive officer of CorMedix, stated in a news release. “We are optimistic that this trial will further our efforts to bring Neutrolin to market in the United States so that more patients can benefit from its use.”

Following FDA approval, Neutrolin will provide CorMedix with access to an underserved market within the biopharmaceutical industry. According to the company’s data, central venous catheters are the most frequent cause of healthcare-associated bloodstream infections, accounting for approximately 25 percent of the 1.7 million recorded hospital infections each year. Among these infections, approximately 20 percent are fatal, further demonstrated the immense market potential of the company’s product.

For prospective shareholders, CorMedix’s continued progress toward commercialization of Neutrolin in the United States could foreshadow an opportunity for the company to realize strong financial growth in the months to come. Look for CorMedix to continue preparing for the initiation of two phase III clinical trials moving forward.

For more information, visit www.cormedix.com

Venaxis, Inc. (NASDAQ: APPY) is an in vitro diagnostic company focused on the development and commercialization of its leading product candidate, the APPY1™ Test. This novel blood-based diagnostic test is designed to aid in the evaluation of patients at low risk for acute appendicitis, allowing physicians to more effectively manage the large number of children and adolescents who enter hospital emergency departments with abdominal pain. Currently, determining if a patient requires emergency surgery for appendicitis normally requires diagnostic CT imaging, which is both expensive and time-intensive. In cases where imaging capacity is limited, patients are often admitted to the hospital in order to avoid the risk of appendicitis rupture at home, which adds significant cost for both patients and hospitals.

When fully commercialized, the APPY1 Test will provide physicians with a more cost-effective approach to diagnosing appendicitis. According to the Centers for Disease Control and Prevention, physicians ordered an estimated 7.5 million blood tests for abdominal pain in 2010, and approximately one million were performed on patients less than 21 years old. Statistically, these young patients have the highest risk of long-term health effects resulting from CT imaging. For this reason, Venaxis is initially developing the APPY1 Test for pediatric, adolescent and young adult patients.

In January, the FDA determined that the Appy1 Test did not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis. As of the company’s latest business update in June, FDA clearance process and status for the APPY1 Test was still under evaluation. However, Venaxis is continuing to advance toward the commercialization of its innovative product through a limited launch in select European countries scheduled to begin in the coming months.

“The FDA decision is very disappointing,” Steve Lundy, president and chief executive officer of Venaxis, stated in a January news release. “We believe that the strong clinical trial results we achieved and the additional clinical utility information we provided to the FDA in response to its requests for additional information were compelling, and we intend to continue to work with the FDA to advance the progress of a blood-based diagnostic test to assist in the evaluation of appendicitis.”

Despite beginning the year with a disappointing FDA ruling, Venaxis has made significant strides toward improved financial results through the continued development of the APPY1 Test. For prospective shareholders, Venaxis’s unwavering commitment to the development of innovative alternatives to current appendicitis diagnostic techniques could provide a platform upon which to realize sustainable returns in the years to come.

For more information, visit www.venaxis.com

ClearSign Combustion Corp. (NASDAQ: CLIR) designs, develops and markets technologies that improve key performance characteristics of combustion systems – including emissions and operational performance, energy efficiency and overall cost-effectiveness. The company’s patent-pending Duplex™ and Electrodynamic Combustion Control™ (ECC) platform technologies are designed to dramatically improve the performance of the world’s commercial, industrial and utility combustion systems. By providing simple retrofit strategies that are utilized during combustion, ClearSign allows its customers to optimize performance at a fraction of the cost of more common legacy after-treatment methods.

The potential market for ClearSign’s products is immense. Nearly two-thirds of global energy consumption can be attributed to the combustion of hydrocarbons and other fuels in boilers, furnaces, kilns and turbines. In the United States, these power generating processes account for more than 50 quadrillion British thermal units (BTUs) of energy each year. As a result of this scale, even modest increases in efficiency can lead to massive savings across a broad range of markets – including the chemical, petrochemical, refinery, power and commercial boiler industries.

In the first quarter of 2015, ClearSign achieved several significant commercial milestones that could set the stage for considerable industry growth in the future. In particular, the company validated the effectiveness of its Duplex technology by demonstrating a meaningful reduction in energy consumption in a field demonstration at Aera Energy in California. Following these results, the company was invited to present its technical results to environmental regulators in Texas, providing a platform upon which to expand its market share in the Lone Star State, which currently refines more than one quarter of the nation’s gasoline. The company also presented its technology to experts from the American Petroleum Institute (API) in April.

“The refinery and petrochemical segment is a significant market opportunity for ClearSign,” Steve Pirnat, chairman and chief executive officer of ClearSign, stated in a news release. “We are very encouraged by the positive feedback we received from the API membership and also believe that successful installations at the two refinery projects already in our trial order backlog will build further confidence and interest in Duplex technology for refinery applications.”

For prospective investors, ClearSign’s recent progress toward industry growth could foreshadow an opportunity for the company to realize improved financial results in the months to come. Look for ClearSign to leverage the strong performance of its proprietary technologies in order to promote sustainable returns moving forward.

For more information, visit www.clearsign.com